Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - PubMed
4 hours ago
- #Clinical Trials
- #Noninvasive Tests
- #MASH Biomarkers
- Liver biopsy remains the gold standard for MASH diagnosis and prognosis but is invasive.
- Noninvasive tests like elastography and enhanced liver fibrosis test are key surrogates.
- These tests aim to reduce biopsy reliance while monitoring disease progression and treatment efficacy.
- They facilitate clinical trials and drug development by providing reliable biomarker assessments.
- This review offers a roadmap for regulators and practitioners to update clinical trial requirements.